Canada Life’s Aegerion Pharmaceuticals AEGR Stock Holding History

Canada Life’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,300	Closed	-$5K	–	2532
2016 Q1	$5K	Hold	1,300	–	–	﹤0.01%	2429
2015 Q4	$13K	Hold	1,300	–	–	﹤0.01%	2407
2015 Q3	$18K	Hold	1,300	–	–	﹤0.01%	2337
2015 Q2	$25K	Hold	1,300	–	–	﹤0.01%	2418
2015 Q1	$34K	Hold	1,300	–	–	﹤0.01%	2228
2014 Q4	$27K	Hold	1,300	–	–	﹤0.01%	2283
2014 Q3	$44K	Hold	1,300	–	–	﹤0.01%	2094
2014 Q2	$42K	Hold	1,300	–	–	﹤0.01%	2027
2014 Q1	$60K	Hold	1,300	–	–	﹤0.01%	1686
2013 Q4	$93K	Buy	+1,300	New	+$99.4K	﹤0.01%	1448

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Canada Life's AEGR Position: Q2 2016 in Review

Canada Life sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 1,300 shares — an estimated $5K sold.

Canada Life first reported a position in AEGR in Q4 2013 and held it in 10 quarters. The position peaked at $93K in Q4 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Canada Life reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Canada Life sold 1,300 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $5K.
Canada Life first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Canada Life's Aegerion Pharmaceuticals position peaked at $93K in Q4 2013.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Canada Life's 13F filing for Q2 2016, filed 3 Aug 2016.